Table 1.

Clinical characterization of melanoma patients.

	Age	Gender	Primary	BRAF status	PFSa (days)	OSb (days)	Disease stage	Treatment response	Type of treatment
1	60	Male	CMMc	V600E	186	696	M1cd	PRe	BRAFif
2	50	Female	CMM	V600E	170	637	M1c	PR	BRAFi
3	32	Male	UKg	V600E	148	248	M1c	PR	BRAFi
4	40	Male	CMM	V600E	101	203	M1c	PR	BRAFi,
5	43	Female	CMM	V600E	562	Alive	M1c	PDh	BRAFi and MEKii

^aProgression-free survival (PFS).

^bOverall survival (OS).

^cCutaneous malignant melanoma (CMM).

^dCutaneous or, subcutaneous metastases (M1c).

^ePartial response (PR).

^fBRAF inhibitor (BRAFi; Dabrafenib/Vemurafenib).

^gUnknown (UK).

^hProgressive disease (PD).

ⁱMEK inhibitor (MEKi; Binimetinib).